

Alexander Schramm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1278734/publications.pdf>

Version: 2024-02-01

136
papers

7,750
citations

57758

44
h-index

56724

83
g-index

144
all docs

144
docs citations

144
times ranked

10877
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 15, 101279.	3.7	7
2	EIF4EBP1 is transcriptionally upregulated by MYCN and associates with poor prognosis in neuroblastoma. <i>Cell Death Discovery</i> , 2022, 8, 157.	4.7	3
3	The clinical utility of <sc>crRNA</sc> for disease detection and surveillance: A proof of concept study in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2022, 13, 2180-2191.	1.9	4
4	Syntaxin 18 regulates the DNA damage response and epithelial-to-mesenchymal transition to promote radiation resistance of lung cancer. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	1
5	Anticancer Effects of <i>Viscum album</i> Fraxini Extract on Medulloblastoma Cells in vitro. <i>Complementary Medicine Research</i> , 2021, 28, 15-22.	1.2	7
6	Druggable epigenetic suppression of interferon-induced chemokine expression linked to <i>MYCN</i> amplification in neuroblastoma. , 2021, 9, e001335.		19
7	NTRK1/TrkA Signaling in Neuroblastoma Cells Induces Nuclear Reorganization and Intra-Nuclear Aggregation of Lamin A/C. <i>Cancers</i> , 2021, 13, 5293.	3.7	7
8	HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2. <i>European Journal of Cancer</i> , 2021, 159, 16-23.	2.8	23
9	Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. <i>Cell Reports</i> , 2021, 37, 110056.	6.4	24
10	NTRK1/TrkA Activation Overrides the G2/M-Checkpoint upon Irradiation. <i>Cancers</i> , 2021, 13, 6023.	3.7	2
11	Streamlining Quantitative Analysis of Long RNA Sequencing Reads. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7259.	4.1	1
12	Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. <i>Oncogenesis</i> , 2020, 9, 102.	4.9	24
13	Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway. <i>Cancer Research</i> , 2020, 80, 4655-4667.	0.9	52
14	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. <i>Cancers</i> , 2020, 12, 353.	3.7	24
15	N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma. <i>Scientific Reports</i> , 2020, 10, 7157.	3.3	19
16	HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. <i>Lung Cancer</i> , 2020, 144, 20-29.	2.0	9
17	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 531.	4.8	20
18	Preclinical Evaluation of Antitumoral and Cytotoxic Properties of <i>Viscum album</i> Fraxini Extract on Pediatric Tumor Cells. <i>Planta Medica</i> , 2019, 85, 1150-1159.	1.3	8

#	ARTICLE	IF	CITATIONS
19	Design, synthesis and biological evaluation of Î²-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity. <i>MedChemComm</i> , 2019, 10, 1109-1115.	3.4	11
20	Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma. <i>Cancer Letters</i> , 2019, 445, 24-33.	7.2	22
21	Cancer evolution, mutations, and clonal selection in relapse neuroblastoma. <i>Cell and Tissue Research</i> , 2018, 372, 263-268.	2.9	21
22	Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy. <i>Complementary Therapies in Medicine</i> , 2018, 40, 158-164.	2.7	20
23	Evolution of melanoma cross-resistance to CD8+ T cells and MAPK inhibition in the course of BRAFi treatment. <i>Oncolmmunology</i> , 2018, 7, e1450127.	4.6	22
24	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	12.6	213
25	TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 718.	4.1	6
26	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. <i>JCI Insight</i> , 2018, 3, .	5.0	28
27	The mutational landscape of <i>MYCN</i> , <i>Lin28b</i> and <i>ALK</i> <i>F1174L</i> driven murine neuroblastoma mimics human disease. <i>Oncotarget</i> , 2018, 9, 8334-8349.	1.8	6
28	Overcoming drug resistance by cell-penetrating peptide-mediated delivery of a doxorubicin dimer with high DNA-binding affinity. <i>European Journal of Medicinal Chemistry</i> , 2017, 130, 336-345.	5.5	31
29	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <i>Oncolmmunology</i> , 2017, 6, e1320626.	4.6	89
30	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	5.0	28
31	Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 288-296.	2.6	8
32	Application of the PAMONO-Sensor for Quantification of Microvesicles and Determination of Nano-Particle Size Distribution. <i>Sensors</i> , 2017, 17, 244.	3.8	23
33	MYCN-mediated murine cancer models. <i>Aging</i> , 2017, 9, 1084-1085.	3.1	3
34	Targeting tachykinin receptors in neuroblastoma. <i>Oncotarget</i> , 2017, 8, 430-443.	1.8	19
35	The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models. <i>Oncotarget</i> , 2017, 8, 6730-6741.	1.8	34
36	RITA displays anti-tumor activity in medulloblastomas independent of <i>TP53</i> status. <i>Oncotarget</i> , 2017, 8, 27882-27891.	1.8	4

#	ARTICLE	IF	CITATIONS
37	Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma. <i>Oncolimmunology</i> , 2016, 5, e1131378.	4.6	18
38	Towards diagnostic application of non-coding RNAs in neuroblastoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1307-1313.	3.1	2
39	MYCN-targeting vaccines and immunotherapeutics. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2257-2258.	3.3	4
40	Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 2470-2481.	7.0	147
41	Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. <i>PLoS ONE</i> , 2016, 11, e0163648.	2.5	5
42	Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. <i>Oncotarget</i> , 2016, 7, 74415-74426.	1.8	21
43	The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse. <i>Oncotarget</i> , 2016, 7, 6620-6625.	1.8	8
44	MIR34a deficiency accelerates medulloblastoma formation in vivo. <i>International Journal of Cancer</i> , 2015, 136, 2293-2303.	5.1	40
45	Absence of telomerase reverse transcriptase promoter mutations in neuroblastoma. <i>Biomedical Reports</i> , 2015, 3, 443-446.	2.0	25
46	Mutational dynamics between primary and relapse neuroblastomas. <i>Nature Genetics</i> , 2015, 47, 872-877.	21.4	253
47	A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. <i>Oncogene</i> , 2015, 34, 3357-3368.	5.9	112
48	Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1215-1227.	4.2	17
49	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	27.8	478
50	miR-542b-3p exerts tumor suppressive functions in neuroblastoma by downregulating Survivin. <i>International Journal of Cancer</i> , 2015, 136, 1308-1320.	5.1	78
51	Abstract LB-210: Telomerase activation by genomic rearrangements in high-risk neuroblastoma. , 2015, , .		5
52	Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. <i>Oncotarget</i> , 2015, 6, 15425-15435.	1.8	37
53	Abstract 4731: Targeting super-enhancer induced gene expression with the novel BRD4 inhibitor OTX015 in preclinical models of MYCN-amplified neuroblastoma. , 2015, , .		0
54	Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling. <i>PLoS ONE</i> , 2014, 9, e108818.	2.5	6

#	ARTICLE	IF	CITATIONS
55	Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. <i>Oncotarget</i> , 2014, 5, 11180-11192.	1.8	26
56	Abstract 3967: BET protein inhibitor OTX015 has selective anti-tumoral activity in preclinical models of MYCN-amplified neuroblastoma. , 2014, , .		0
57	MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. <i>Oncogene</i> , 2013, 32, 1059-1065.	5.9	84
58	Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. <i>Oncogene</i> , 2013, 32, 2927-2936.	5.9	84
59	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 19.	5.2	26
60	Discovery of a New Bioactive Molecule for Neuroblastoma. <i>Chemical Biology and Drug Design</i> , 2013, 82, 233-241.	3.2	3
61	The BCL2-938 C&A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. <i>BMC Cancer</i> , 2013, 13, 452.	2.6	8
62	MiR&137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. <i>International Journal of Cancer</i> , 2013, 133, 1064-1073.	5.1	91
63	Identifying transcriptional miRNA biomarkers by integrating high-throughput sequencing and real-time PCR data. <i>Methods</i> , 2013, 59, 154-163.	3.8	10
64	Next&generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in <i>MYCN&/i>amplified neuroblastoma. <i>International Journal of Cancer</i> , 2013, 132, E106-15.	5.1	26
65	Targeted Therapy for Neuroblastoma: ALK Inhibitors. <i>Klinische Padiatrie</i> , 2013, 225, 303-308.	0.6	29
66	Expression of NTRK1/TrkA affects immunogenicity of neuroblastoma cells. <i>International Journal of Cancer</i> , 2013, 133, 908-919.	5.1	20
67	Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction. <i>Scientific Reports</i> , 2013, 3, 1351.	3.3	34
68	Design of a Modular Protein-Based MRI Contrast Agent for Targeted Application. <i>PLoS ONE</i> , 2013, 8, e65346.	2.5	13
69	Focal DNA Copy Number Changes in Neuroblastoma Target MYCN Regulated Genes. <i>PLoS ONE</i> , 2013, 8, e52321.	2.5	37
70	BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. <i>Oncotarget</i> , 2013, 4, 2080-2095.	1.8	122
71	Abstract 4596: LIN28B drives neuroblastoma oncogenesis through let7-MYCN signaling.. , 2013, , .		0
72	Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. <i>Neuro-Oncology</i> , 2012, 14, 859-869.	1.2	48

#	ARTICLE	IF	CITATIONS
73	Smac Mimetic LBW242 Sensitizes XIAP-Overexpressing Neuroblastoma Cells for TNF-Independent Apoptosis. <i>Cancer Research</i> , 2012, 72, 2645-2656.	0.9	41
74	The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. <i>Cell Cycle</i> , 2012, 11, 569-581.	2.6	30
75	Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice. <i>Science Translational Medicine</i> , 2012, 4, 141ra91.	12.4	147
76	Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome. <i>British Journal of Cancer</i> , 2012, 107, 1409-1417.	6.4	24
77	Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation. <i>Leukemia</i> , 2012, 26, 2039-2051.	7.2	171
78	Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. <i>Nature Cell Biology</i> , 2012, 14, 958-965.	10.3	79
79	Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. <i>BMC Bioinformatics</i> , 2012, 13, S13.	2.6	15
80	LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. <i>Nature Genetics</i> , 2012, 44, 1199-1206.	21.4	336
81	<i>Dickkopf3</i> is regulated by the MYCN-induced miR-17-92 cluster in neuroblastoma. <i>International Journal of Cancer</i> , 2012, 130, 2591-2598.	5.1	43
82	Identification of a novel recurrent 1q42.2qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. <i>International Journal of Cancer</i> , 2012, 130, 2599-2606.	5.1	37
83	Abstract 1683: ALK F1174L kinase activity as driver of cell proliferation in neuroblastoma cell line models and neuroblastoma tumors. , 2012, , .		0
84	Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. <i>Oncogene</i> , 2011, 30, 2823-2835.	5.9	27
85	Regulatory BCL2 promoter polymorphism (rs938) is associated with adverse outcome in patients with prostate carcinoma. <i>International Journal of Cancer</i> , 2011, 129, 2390-2399.	5.1	39
86	miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor Samples. <i>Clinical Cancer Research</i> , 2011, 17, 7684-7692.	7.0	92
87	Polo-Like Kinase 1 is a Therapeutic Target in High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 731-741.	7.0	67
88	High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma. <i>Clinical Cancer Research</i> , 2011, 17, 5082-5092.	7.0	95
89	IL-2 driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16+ Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion. <i>Journal of Immunotherapy</i> , 2010, 33, 200-210.	2.4	89
90	Accurate prediction of neuroblastoma outcome based on miRNA expression profiles. <i>International Journal of Cancer</i> , 2010, 127, 2374-2385.	5.1	88

#	ARTICLE	IF	CITATIONS
91	MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. <i>Oncogene</i> , 2010, 29, 1394-1404.	5.9	112
92	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. <i>Oncogene</i> , 2010, 29, 3583-3592.	5.9	141
93	Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q ^â Neuroblastoma. <i>Clinical Cancer Research</i> , 2010, 16, 2971-2978.	7.0	70
94	The miR-17-92 MicroRNA Cluster Regulates Multiple Components of the TGF- β Pathway in Neuroblastoma. <i>Molecular Cell</i> , 2010, 40, 762-773.	9.7	279
95	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. <i>Clinical Cancer Research</i> , 2010, 16, 1532-1541.	7.0	86
96	Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma. <i>Nucleic Acids Research</i> , 2010, 38, 5919-5928.	14.5	183
97	Meta-analysis of Neuroblastomas Reveals a Skewed <i>ALK</i> Mutation Spectrum in Tumors with <i>MYCN</i> Amplification. <i>Clinical Cancer Research</i> , 2010, 16, 4353-4362.	7.0	243
98	Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2392-2401.	4.1	23
99	Meta-mining of Neuroblastoma and Neuroblast Gene Expression Profiles Reveals Candidate Therapeutic Compounds. <i>Clinical Cancer Research</i> , 2009, 15, 3690-3696.	7.0	41
100	Lysine-Specific Demethylase 1 Is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy. <i>Cancer Research</i> , 2009, 69, 2065-2071.	0.9	405
101	The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells <i>in vivo</i> . <i>International Journal of Cancer</i> , 2009, 124, 2488-2494.	5.1	15
102	Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. <i>Oncogene</i> , 2009, 28, 2015-2023.	5.9	61
103	MicroRNAs in the pathogenesis of neuroblastoma. <i>Cancer Letters</i> , 2009, 274, 10-15.	7.2	37
104	Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction. <i>Cancer Letters</i> , 2009, 282, 55-62.	7.2	10
105	Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics. <i>International Journal of Cancer</i> , 2008, 122, 1177-1182.	5.1	22
106	MYCN regulates oncogenic MicroRNAs in neuroblastoma. <i>International Journal of Cancer</i> , 2008, 122, 699-704.	5.1	251
107	CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23. <i>BMC Cancer</i> , 2008, 8, 173.	2.6	34
108	Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells. <i>DNA Repair</i> , 2008, 7, 1757-1764.	2.8	18

#	ARTICLE	IF	CITATIONS
109	Transcription factor AP2alpha (TFAP2a) regulates differentiation and proliferation of neuroblastoma cells. <i>Cancer Letters</i> , 2008, 271, 56-63.	7.2	29
110	Targeting the Phosphoinositide 3-Kinase Isoform p110 β Impairs Growth and Survival in Neuroblastoma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 1172-1181.	7.0	63
111	Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: A mechanism to inhibit invasion. <i>International Journal of Oncology</i> , 2008, , .	3.3	9
112	Translating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 1459-1465.	7.0	28
113	Fractalkine (CX3CL1) and Interleukin-2 Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells. <i>Cancer Research</i> , 2007, 67, 2331-2338.	0.9	62
114	High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. <i>International Journal of Cancer</i> , 2007, 120, 533-538.	5.1	20
115	ArrayCGH-based classification of neuroblastoma into genomic subgroups. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1098-1108.	2.8	67
116	Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. <i>Genome Biology</i> , 2006, 7, R84.	9.6	134
117	Keratoepithelin Suppresses the Progression of Experimental Human Neuroblastomas. <i>Cancer Research</i> , 2006, 66, 5314-5321.	0.9	36
118	Identification of a Set of Seven Genes for the Monitoring of Minimal Residual Disease in Pediatric Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 2434-2441.	7.0	111
119	Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. <i>Oncogene</i> , 2005, 24, 165-177.	5.9	76
120	High activin A-expression in human neuroblastoma: suppression of malignant potential and correlation with favourable clinical outcome. <i>Oncogene</i> , 2005, 24, 680-687.	5.9	33
121	Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. <i>Oncogene</i> , 2005, 24, 6441-6449.	5.9	108
122	Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling. <i>Oncogene</i> , 2005, 24, 7902-7912.	5.9	113
123	Identification of Dynamic Proteome Changes Upon Ligand Activation of Trk-Receptors Using Two-dimensional Fluorescence Difference Gel Electrophoresis and Mass Spectrometry. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 291-299.	3.8	36
124	Application of microarray-based technology to neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 13-20.	7.2	13
125	Phox2B mutations and the Delta Notch pathway in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 59-63.	7.2	27
126	Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 143-153.	7.2	106

#	ARTICLE	IF	CITATIONS
127	The Phox2B homeobox gene is mutated in sporadic neuroblastomas. <i>Oncogene</i> , 2004, 23, 9280-9288.	5.9	112
128	Structure and Function of a Regulated Archaeal Triosephosphate Isomerase Adapted to High Temperature. <i>Journal of Molecular Biology</i> , 2004, 342, 861-875.	4.2	32
129	Microarray-Analysis: A New Approach to Study the Molecular Mechanisms of Thermo-Chemotherapy. <i>Klinische Padiatrie</i> , 2003, 215, 298-302.	0.6	12
130	Proteomics: Techniques and Applications in Cancer Research. <i>Klinische Padiatrie</i> , 2003, 215, 293-297.	0.6	13
131	Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays. <i>International Journal of Oncology</i> , 2002, 20, 441.	3.3	30
132	[6] Triose-phosphate isomerase from <i>Pyrococcus woesei</i> and <i>Methanothermus fervidus</i> . <i>Methods in Enzymology</i> , 2001, 331, 62-77.	1.0	9
133	Pyruvate Kinase of the Hyperthermophilic Crenarchaeote <i>Thermoproteus tenax</i> : Physiological Role and Phylogenetic Aspects. <i>Journal of Bacteriology</i> , 2000, 182, 2001-2009.	2.2	66
134	Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. <i>Gastroenterology</i> , 1996, 110, 1215-1224.	1.3	122
135	Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines. <i>British Journal of Haematology</i> , 1995, 91, 350-354.	2.5	30
136	Characterization and chromosomal assignment of yeast artificial chromosomes containing human 3p13-p21-specific sequence tagged sites. <i>Cancer Genetics and Cytogenetics</i> , 1995, 81, 1-12.	1.0	19